Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators.

Circulation. 2002 Nov 5;106(19):2454-8.

2.

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN; Val-HeFT Investigators.

Circulation. 2003 Mar 11;107(9):1278-83.

3.

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.

Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN; Val-HeFT Investigators (Valsartan Heart Failure Trial).

J Am Coll Cardiol. 2002 Oct 16;40(8):1414-21.

4.

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.

Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R; Valsartan Heart Failure Trial Investigators.

Circulation. 2003 Sep 16;108(11):1306-9. Epub 2003 Aug 25.

5.

[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].

Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.

Ter Arkh. 2006;78(8):14-20. Russian.

PMID:
17078211
7.

[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].

Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.

Ter Arkh. 2006;78(9):61-71. Russian.

PMID:
17076227
8.

Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.

Am Heart J. 2004 Jul;148(1):122-8.

PMID:
15215801
10.

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).

Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.

Am Heart J. 2004 Dec;148(6):951-7.

PMID:
15632877
11.

Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.

Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, Cohn JN, Tavazzi L.

J Card Fail. 2005 May;11(4):253-9. Erratum in: J Card Fail. 2005 Jun;11(5):404.

PMID:
15880333
12.

Effect of Valsartan on hospitalization: results from Val-HeFT.

Carson P, Tognoni G, Cohn JN.

J Card Fail. 2003 Jun;9(3):164-71.

PMID:
12815565
13.

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN; Val-HeFT Heart Failure Trial Investigators.

J Am Coll Cardiol. 2002 Sep 4;40(5):970-5.

14.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

15.

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN; Val-HeFT Investigators.

Am Heart J. 2005 Mar;149(3):548-57.

PMID:
15864246
16.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators.

N Engl J Med. 2001 Dec 6;345(23):1667-75.

17.

Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.

Cohn JN, Tognoni G, Glazer R, Spormann D.

Eur J Heart Fail. 2000 Dec;2(4):439-46.

18.

Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.

Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, Cohn JN, Tognoni G, Latini R; Valsartan Heart Failure Trial Investigators.

J Card Fail. 2007 Dec;13(10):797-804.

PMID:
18068611
19.

The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.

Tan LB, Schlosshan D, Williams SG.

Int J Clin Pract. 2004 Feb;58(2):184-91.

PMID:
15055867
20.

Valsartan in heart failure patients previously untreated with an ACE inhibitor.

Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, Orlov VA, Olbinskaya LI, Bolshakova TD, Sullivan J, Spormann DO.

Int J Cardiol. 1998 Aug;65(3):239-46.

PMID:
9740480
Items per page

Supplemental Content

Write to the Help Desk